XTX Topco Ltd grew its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS – Free Report) by 101.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 49,616 shares of the company’s stock after buying an additional 24,951 shares during the period. XTX Topco Ltd’s holdings in Atossa Therapeutics were worth $75,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Intech Investment Management LLC bought a new position in Atossa Therapeutics during the third quarter worth $29,000. SG Americas Securities LLC lifted its position in shares of Atossa Therapeutics by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after buying an additional 30,037 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Atossa Therapeutics in the 3rd quarter valued at about $75,000. State Street Corp grew its position in shares of Atossa Therapeutics by 4.2% during the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company’s stock valued at $2,633,000 after buying an additional 69,180 shares during the last quarter. Finally, Rhumbline Advisers acquired a new stake in Atossa Therapeutics during the second quarter worth about $161,000. Institutional investors and hedge funds own 12.74% of the company’s stock.
Atossa Therapeutics Trading Down 1.7 %
Shares of NASDAQ ATOS opened at $0.96 on Friday. Atossa Therapeutics, Inc. has a 12-month low of $0.72 and a 12-month high of $2.31. The company has a market cap of $121.23 million, a PE ratio of -4.38 and a beta of 1.21. The stock has a 50 day simple moving average of $1.31 and a 200-day simple moving average of $1.32.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on ATOS
About Atossa Therapeutics
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Further Reading
- Five stocks we like better than Atossa Therapeutics
- What is Short Interest? How to Use It
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- What Are Dividend Challengers?
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- Business Services Stocks Investing
- MarketBeat Week in Review – 12/16 – 12/20
Want to see what other hedge funds are holding ATOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atossa Therapeutics, Inc. (NASDAQ:ATOS – Free Report).
Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.